Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > GH/IGF-1 effect on IHL among people with or without GHD

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Apr 28, 2023 8:04pm

98 Views

Post# 35420362

RE:GH/IGF-1 effect on IHL among people with or without GHD

The growth hormone disorder mentioned here was referring to excessive production of GH nevertheless the point is people with normal growth hormone levels and of course with GHD stilll will have reduced liver fat due to increased levels of GH/IGF-1.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec